AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 19660610
Drug: Simvastatin monotherapy
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Simvastatin monotherapy (20 mg)
Trial: 8489751
Drug: Levonova (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levonova (20 micrograms levonorgestrel daily)
Trial: 28604115
Drug: xyloglucan-based nasal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: xyloglucan-based nasal spray
Trial: 28604115
Drug: saline nasal
RxNorm normalized name: Ayr Saline Nasal
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: saline nasal spray
Trial: 25888571
Drug: White blood
RxNorm normalized name: Human white blood cell product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: White blood cell count >10.6 × 10^9/L
Trial: 25888571
Drug: PAI-1 >12.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PAI-1 >12.2 IU/mL
Trial: 22776634
Drug: Lurasidone 120
RxNorm normalized name: lurasidone 120 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lurasidone 120 mg/d
Trial: 22776634
Drug: Quetiapine extended-release
RxNorm normalized name: Quetiapine Extended-Release Tablets
DrugBank: Quetiapine (DB01224)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Quetiapine extended-release 600 mg/d
Trial: 22776634
Drug: Lurasidone 40-120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lurasidone 40-120 mg/d
Trial: 19820238
Drug: Fixed-dose regimens
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed-dose regimens in RCTs
Trial: 11934658
Drug: 1 mg
RxNorm normalized name: biotin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg estradiol combined with gestodene
Trial: 11934658
Drug: 2 mg
RxNorm normalized name: iodine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg estradiol combined with gestodene
Trial: 11934658
Drug: Piperazine, estrone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Piperazine, estrone sulfate in combination with norethisterone
Trial: 2189248
Drug: Proguanil at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Proguanil at 200 mg/d combined with sulphafurazole at 25 mg/kg/d
Trial: 2189248
Drug: Proguanil at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Proguanil at 200 mg/d combined with sulphamethoxazole at 25 mg/kg/d
Trial: 2189248
Drug: Proguanil at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Proguanil at 200 mg/d combined with sulphamethoxazole at 10 mg/kg/d
Trial: 17264336
Drug: Concurrent chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent chemotherapy (CT) and radiotherapy (RT)
Trial: 17264336
Drug: Sequential chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential chemotherapy (CT) followed by radiotherapy (RT)
Trial: 9329641
Drug: 60 mg
RxNorm normalized name: opium 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 mg vitamin C/day
Trial: 9329641
Drug: 6 g
RxNorm normalized name: FAPi-46 GA-68
DrugBank: FAPi-46 GA-68 (DB18827)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 g vitamin C/day
Trial: 9329641
Drug: Vitamin C
RxNorm normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin C supplementation (both doses)
Trial: 8172789
Drug: Epirubicin (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epirubicin (100 mg/m2 every three weeks, escalating to a maximum of 140 mg/m2)
Trial: 8172789
Drug: Fluorouracil (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluorouracil (500 mg/m2 days 1‐5 every three weeks, escalating to a maximum of 700 mg/m2)
Trial: 29880257
Drug: KaempMax™ (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: KaempMax™ (100 mg daily for 30 days)
Trial: 25239491
Drug: Bilateral intramuscular
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bilateral intramuscular administration of cytokine‐mobilized CD133+ cells (50-400 million cells)
Trial: 25239491
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline injections, sham leukapheresis, and intramuscular injection of placebo buffered solution
Trial: 18819393
Drug: Hyperbaric oxygen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyperbaric oxygen therapy (HBO) for 3 days (twice a day) using a monoplace chamber under pressures of 1.7‐1.9 ATA
Trial: 18819393
Drug: Standardized treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standardized treatment protocol (Control)
Trial: 12012623
Drug: Oral estradiol
RxNorm normalized name: estradiol Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral estradiol 4 mg/day (group A)
Trial: 12012623
Drug: Oral estradiol
RxNorm normalized name: estradiol Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral estradiol 6 mg/day (group B)
Trial: 10631416
Drug: Paracetamol 2
RxNorm normalized name: Paracetamol 24 mg/mL oral solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paracetamol 2 g through a nasogastric tube
Trial: 10631416
Drug: Rectal paracetamol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rectal paracetamol 2 g
Trial: 10631416
Drug: Standard doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard doses of paracetamol (6 g/day) on day 1 after cardiac surgery
Trial: 30575239
Drug: Neoadjuvant chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant chemotherapy with irinotecan (60 mg/m2 on days 1 and 8) and nedaplatin (80 mg/m2 on day 1 of every 21‐day cycle) followed by radical hysterectomy and adjuvant chemotherapy.
Trial: 22079390
Drug: Nutraceuticals (coenzyme
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nutraceuticals (coenzyme Q(10), RRR‐α‐tocopherol, selenium aspartate, and L‐methionine) with cryotherapy for HPV warts
Trial: 22079390
Drug: Nutraceuticals (coenzyme
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nutraceuticals (coenzyme Q(10), RRR‐α‐tocopherol, selenium aspartate, and L‐methionine) with acyclovir for herpes infections
Trial: 22079390
Drug: Nutraceuticals (coenzyme
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nutraceuticals (coenzyme Q(10), RRR‐α‐tocopherol, selenium aspartate, and L‐methionine)
Trial: 19671308
Drug: Glucagon injection
RxNorm normalized name: glucagon Injection
DrugBank: Glucagon (DB00040)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Glucagon injection
Trial: 17498005
Drug: KRN321 (darbepoetin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: KRN321 (darbepoetin alfa) administered at extended dose intervals (once per week or once every two weeks)
Trial: 15170885
Drug: 1 g/m2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 g/m2 MTX as a 24-hr infusion
Trial: 15170885
Drug: 2 g/m2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 g/m2 MTX as a 24-hr infusion
Trial: 11587466
Drug: Classical SDD
RxNorm normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Classical SDD regimen (tobramycin 80 mg, polymyxin E 100 mg, amphotericin B 500 mg)
Trial: 11587466
Drug: Modified SDD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modified SDD regimen with mupirocin (2% mupirocin ointment applied four times daily in nostrils and modified oral paste)
Trial: 9838776
Drug: Spray group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spray group
Trial: 782468
Drug: sodium pentosan
RxNorm normalized name: Pentosan Polysulfate Sodium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sodium pentosan polysulphate/nicotinic acid combination (Compuron)
Trial: 11086616
Drug: SF-36 plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SF-36 plus a form assessing amount of treatment received
Trial: 23086244
Drug: Conventional management
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional management plus intravenous infusion of octreotide, 50 μg/h for 72 hours (obese-C+O)
Trial: 15752371
Drug: Amyl nitrite
RxNorm normalized name: Amyl Nitrite
DrugBank: Amyl Nitrite (DB01612)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amyl nitrite (0.2 ml inhaled for 30 s)
Trial: 15752371
Drug: Glyceryl trinitrate
RxNorm normalized name: Glyceryl trinitrate
DrugBank: Nitroglycerin (DB00727)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Glyceryl trinitrate (0.5 mg for 3 min)
Trial: 10730758
Drug: VML 295
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VML 295 (LY-293111) 200 mg twice daily for 8 weeks
Trial: 9377614
Drug: Mometasone furoate
RxNorm normalized name: Mometasone Furoate
DrugBank: Mometasone furoate (DB14512)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Mometasone furoate 0.1%-salicylic acid 5% ointment, applied twice daily for 21 days
Trial: 9377614
Drug: Fluocinonide 0.05%
RxNorm normalized name: FLUOCINONIDE 0.05% OINT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluocinonide 0.05% ointment, applied twice daily for 21 days
Trial: 3873372
Drug: Aspirin (3.9
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin (3.9 g/day)
Trial: 3873372
Drug: Aspirin (1.95
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin (1.95 g/day) with Acetaminophen (1.95 g/day)
Trial: 3873372
Drug: Aspirin (2.6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin (2.6 g/day) with Acetaminophen (2.6 g/day)
Trial: 27255504
Drug: Multifaceted intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Multifaceted intervention including academic detailing, medicine review with web-based pharmaceutical treatment algorithms, and tailored patient information leaflets.
Trial: 20515625
Drug: Interventional training
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interventional training program for primary care physicians on beta-blocker use
Trial: 12540404
Drug: Dual-fortified salt
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dual-fortified salt (DFS) containing 25 micro g iodine/g salt and 1 mg iron/g salt
Trial: 8707361
Drug: Amphotericin B
RxNorm normalized name: Amphotericin B
DrugBank: Amphotericin B (DB00681)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amphotericin B (AMB) 1 mg/kg bw/day for 20 days
Trial: 8707361
Drug: Amphotericin B
RxNorm normalized name: Amphotericin B
DrugBank: Amphotericin B (DB00681)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amphotericin B (AMB) 0.75 mg/kg bw/day for 20 days
Trial: 8707361
Drug: Amphotericin B
RxNorm normalized name: Amphotericin B
DrugBank: Amphotericin B (DB00681)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amphotericin B (AMB) 0.5 mg/kg bw/day for 20 days
Trial: 26967690
Drug: Anastrozole (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anastrozole (1 mg daily) for 6 weeks
Trial: 16516511
Drug: Loratadine (10mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Loratadine (10mg daily)
Trial: 16516511
Drug: Montelukast (10mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Montelukast (10mg daily)
Trial: 1977089
Drug: Nizatidine 150
RxNorm normalized name: nizatidine 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nizatidine 150 mg b.d.
Trial: 341950
Drug: mianserin 60
RxNorm normalized name: mianserin 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mianserin 60 mg daily
Trial: 341950
Drug: imipramine 150
RxNorm normalized name: imipramine pamoate 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: imipramine 150 mg daily
Trial: 31527377
Drug: Bifiprost® +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bifiprost® + Serenoa Repens 320 mg
Trial: 31527377
Drug: Serenoa Repens
RxNorm normalized name: Serenoa Repens Fruit
DrugBank: Saw palmetto (DB14360)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Serenoa Repens 320 mg alone
Trial: 27788498
Drug: Irinotecan plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Irinotecan plus cisplatin (IP) followed by octreotide long-acting release (LAR) maintenance treatment
Trial: 27788498
Drug: Irinotecan plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Irinotecan plus cisplatin (IP) followed by octreotide LAR maintenance treatment in high proliferation NET group
Trial: 27788498
Drug: Irinotecan plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Irinotecan plus cisplatin (IP) followed by octreotide LAR maintenance treatment in poorly differentiated NEC (PDNEC) group
Trial: 16737936
Drug: 900 mg
RxNorm normalized name: diosmin 900 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 900 mg of oral valganciclovir
Trial: 16737936
Drug: 5 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg/kg of intravenous ganciclovir
Trial: 3527086
Drug: Azathioprine (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azathioprine (1 mg/kg for the first month, 2 mg/kg for the second month)
Trial: 25424809
Drug: 4CMenB vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4CMenB vaccine with prophylactic paracetamol
Trial: 25424809
Drug: 4CMenB vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4CMenB vaccine without prophylactic paracetamol
Trial: 25424809
Drug: Routine infant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine infant vaccines (DTaP-HBV-IPV/Hib and PCV7) with 4CMenB
Trial: 25424809
Drug: Routine infant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine infant vaccines (DTaP-HBV-IPV/Hib and PCV7) with MenC
Trial: 12114877
Drug: Deep injection
RxNorm normalized name: Deep Sea
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Deep injection of radiotracer (group B)
Trial: 12114877
Drug: Superficial injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Superficial injection of radiotracer (group A)
Trial: 12114877
Drug: Deep injection
RxNorm normalized name: Deep Sea
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Deep injection of radiotracer (in outer quadrant patients)
Trial: 7757308
Drug: Nimodipine (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nimodipine (30 mg t.i.d.) with Propranolol (40 mg t.i.d.)
Trial: 30070034
Drug: Micro-needle mesotherapy
RxNorm normalized name: Salicylic Acid 0.002 TOPICAL PATCH [Egg micro needle soothing]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Micro-needle mesotherapy with 20% L-ascorbic acid serum
Trial: 30070034
Drug: No-needle mesotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No-needle mesotherapy with 20% L-ascorbic acid serum
Trial: 29161260
Drug: Delivery arm
RxNorm normalized name: ARM-210
DrugBank: ARM-210 (DB16944)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delivery arm (direct distribution of an oral HIVST from the peer educator)
Trial: 29161260
Drug: Coupon arm
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Coupon arm (a coupon for collection of an oral HIVST from a health clinic/pharmacy)
Trial: 25627884
Drug: Yakult® (Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Yakult® (Treatment A)
Trial: 25627884
Drug: Batavito® (Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Batavito® (Treatment B)
Trial: 25627884
Drug: Yakult® (Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Yakult® (Treatment C)
Trial: 25627884
Drug: Batavito® (Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Batavito® (Treatment D)
Trial: 22746245
Drug: Microdose lithium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Microdose lithium treatment (300 μg, administered once daily for 15 months)
Trial: 22746245
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (not specified, but implied to be without lithium treatment)
Trial: 21684478
Drug: Atorvastatin 40mg
RxNorm normalized name: AMLODIPINE 5MG/ATORVASTATIN 40MG TAB
DrugBank: Atorvastatin (DB01076)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Atorvastatin 40mg for 8 months
Trial: 16468063
Drug: Shoulder-to-hand distance
RxNorm normalized name: Head & Shoulders
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Shoulder-to-hand distance (l)
Trial: 12846597
Drug: Diazepam 0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diazepam 0.1 mg/kg (IV infusion)
Trial: 8364132
Drug: 60 mg/day
RxNorm normalized name: cabozantinib s-malate 60 mg/day (20 mg x 3/day) ORAL CAPSULE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 mg/day ZnSO4
Trial: 8364132
Drug: 200 mg/day
RxNorm normalized name: alpelisib 200 mg/day (200 mg x 1) ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg/day ZnSO4
Trial: 3538460
Drug: misonidazole (1
RxNorm normalized name: Fluoromisonidazole (18-F)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: misonidazole (1 g/m2 body surface)
Trial: 29728296
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of Buzzy® and animated cartoon
Trial: 25370571
Drug: Psychological intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Psychological intervention (cognitive behavioural therapy combined with counselling techniques)
Trial: 8911981
Drug: Glimepiride (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glimepiride (5 mg)
Trial: 31178508
Drug: Kikyo-to (KKT)
RxNorm normalized name: Wong To Yick
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Kikyo-to (KKT) 2.5 g
Trial: 19688837
Drug: Oral midazolam
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oral midazolam (0.3 mg/kg body weight, maximum 10 mg)
Trial: 9695587
Drug: Adjuvant laferon
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant laferon therapy (intraperitoneal and systemic administration)
Trial: 8077355
Drug: 0.2 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.2 mg/kg L-692,429, i.v. preceded by 4 days of prednisolone (20 mg, orally, three times daily)
Trial: 8077355
Drug: 0.75 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.75 mg/kg L-692,429 preceded by prednisolone only
Trial: 8077355
Drug: 0.2 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.2 mg/kg L-692,429 in the absence of steroid
Trial: 2491941
Drug: (-)-deprenyl (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: (-)-deprenyl (30 mg/d)
Trial: 31068063
Drug: VTC-administered ADAS-cog
RxNorm normalized name: Adasuve
DrugBank: Loxapine (DB00408)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: VTC-administered ADAS-cog
Trial: 31068063
Drug: FTF-administered ADAS-cog
RxNorm normalized name: Adasuve
DrugBank: Loxapine (DB00408)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: FTF-administered ADAS-cog
Trial: 24258468
Drug: Strefen lozenges
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Strefen lozenges
Trial: 24258468
Drug: Siccoral spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Siccoral spray
Trial: 22023081
Drug: Haberlea extract
RxNorm normalized name: Haberlea rhodopensis leaf extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Haberlea extract (3% in cream)
Trial: 18174071
Drug: Midpalatal implants
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midpalatal implants
Trial: 8963856
Drug: Sequential surgery
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential surgery (SS)
Trial: 2045624
Drug: Pyridostigmine (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pyridostigmine (60 mg po)
Trial: 2045624
Drug: PD +
RxNorm normalized name: Dianeal PD-2/2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PD + GHRH (60 mg PD orally 60 min before GHRH)
Trial: 7389390
Drug: Single night-time
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single night-time dose of chlordiazepoxide (5 mg) and amitriptyline (12.5 mg) - 3 capsules as a single dose at night
Trial: 7389390
Drug: Divided daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Divided daily dosage regimen of chlordiazepoxide (5 mg) and amitriptyline (12.5 mg) - 1 capsule 3-times daily
Trial: 25873137
Drug: internet-based cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: internet-based cognitive behavior therapy (iCBT)
Trial: 21318572
Drug: Romiplostim (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Romiplostim (1 μg/kg/week, escalated to 5 μg/kg/week, tapered over 12 weeks)
Trial: 20532105
Drug: Oral midazolam
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oral midazolam 0.5 mg/kg mixed with ibuprofen 10 mg/kg (Group M)
Trial: 20532105
Drug: Oral midazolam
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oral midazolam 0.5 mg/kg mixed with ibuprofen 10 mg/kg and ketamine 2 mg/kg (Group KM)
Trial: 9201140
Drug: IVIG 250
RxNorm normalized name: Intravenous immunoglobulin (IVIg)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IVIG 250 mg/kg/day for 2 days
Trial: 9201140
Drug: IVIG 400
RxNorm normalized name: Intravenous immunoglobulin (IVIg)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IVIG 400 mg/kg/day for 2 days
Trial: 9201140
Drug: IVIG 500
RxNorm normalized name: Intravenous immunoglobulin (IVIg)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IVIG 500 mg/kg/day for 2 days
Trial: 9201140
Drug: IVIG 1
RxNorm normalized name: Intravenous immunoglobulin (IVIg)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IVIG 1 g/kg/day for 2 days (control)
Trial: 24526895
Drug: Psychotherapeutic Intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Psychotherapeutic Intervention Module (PIM), n = 90, six therapy sessions over two months.
Trial: 24526895
Drug: Treatment as
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment as Usual (TAU), n = 83.
Trial: 20102918
Drug: Red yeast
RxNorm normalized name: red yeast
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Red yeast rice 2,400 mg twice daily